MA41313A - Anticorps de liaison de la protéine april modifiés - Google Patents

Anticorps de liaison de la protéine april modifiés

Info

Publication number
MA41313A
MA41313A MA041313A MA41313A MA41313A MA 41313 A MA41313 A MA 41313A MA 041313 A MA041313 A MA 041313A MA 41313 A MA41313 A MA 41313A MA 41313 A MA41313 A MA 41313A
Authority
MA
Morocco
Prior art keywords
protein binding
binding antibodies
april protein
modified april
modified
Prior art date
Application number
MA041313A
Other languages
English (en)
Inventor
David Lutje Hulsik
Jan Paul Medema
Eenennaam Hans Van
Elsas Andrea Van
Original Assignee
Aduro Biotech Holdings Europe B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aduro Biotech Holdings Europe B V filed Critical Aduro Biotech Holdings Europe B V
Publication of MA41313A publication Critical patent/MA41313A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
MA041313A 2015-01-09 2016-01-08 Anticorps de liaison de la protéine april modifiés MA41313A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL2014108A NL2014108B1 (en) 2015-01-09 2015-01-09 Altered april binding antibodies.

Publications (1)

Publication Number Publication Date
MA41313A true MA41313A (fr) 2021-05-12

Family

ID=53783809

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041313A MA41313A (fr) 2015-01-09 2016-01-08 Anticorps de liaison de la protéine april modifiés

Country Status (20)

Country Link
US (4) US9969808B2 (fr)
EP (2) EP3242892B1 (fr)
JP (2) JP6824190B2 (fr)
KR (2) KR102612373B1 (fr)
CN (1) CN107207602B (fr)
AU (1) AU2016205977B2 (fr)
BR (1) BR112017014771A2 (fr)
CA (1) CA2973286A1 (fr)
DK (1) DK3242892T3 (fr)
EA (1) EA201791270A1 (fr)
ES (1) ES2902901T3 (fr)
HK (1) HK1243435A1 (fr)
IL (1) IL253306B (fr)
MA (1) MA41313A (fr)
MX (2) MX2017009052A (fr)
NL (1) NL2014108B1 (fr)
PL (1) PL3242892T3 (fr)
SG (1) SG11201705589UA (fr)
WO (1) WO2016110587A1 (fr)
ZA (2) ZA201704920B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
DK3380522T3 (da) 2015-11-25 2024-01-22 Visterra Inc Antistofmolekyler til april og anvendelser deraf
IL259931B2 (en) 2015-12-16 2024-02-01 Gritstone Bio Inc Identification of neo-antigens, preparation, and use
CA3064632A1 (fr) * 2017-06-20 2018-12-27 Dana-Farber Cancer Institute, Inc. Procedes de modulation de lymphocytes t regulateurs, de lymphocytes b regulateurs et de reponses immunitaires a l'aide de modulateurs de l'interaction avril-taci
AU2018348165A1 (en) 2017-10-10 2020-05-21 Gritstone Bio, Inc. Neoantigen identification using hotspots
KR20200090855A (ko) 2017-11-22 2020-07-29 그릿스톤 온콜로지, 인코포레이티드 신생항원에 대한 접합 에피토프 제시 감소
US20200190163A1 (en) * 2018-10-26 2020-06-18 Lijun Wu Humanized bcma-car-t cells
WO2020144535A1 (fr) 2019-01-08 2020-07-16 Aduro Biotech Holdings, Europe B.V. Méthodes et compositions de traitement de myélome multiple
WO2021076554A1 (fr) * 2019-10-15 2021-04-22 Dragonfly Therapeutics, Inc. Anticorps ciblant les flt3 et leur utilisation
MX2022004430A (es) * 2019-10-15 2022-07-19 Dragonfly Therapeutics Inc Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), al cumulo de diferenciacion 16 (cd16) y a la tirosina cinasa 3 similar a fms (flt3).
BR112022024262A2 (pt) * 2020-05-29 2023-02-23 Chinook Therapeutics Inc Métodos de tratamento de nefropatia por iga com um anticorpo de ligação a april
US11883432B2 (en) 2020-12-18 2024-01-30 Century Therapeutics, Inc. Chimeric antigen receptor system with adaptable receptor specificity
KR20240019124A (ko) 2021-05-07 2024-02-14 알파인 이뮨 사이언시즈, 인코포레이티드 Taci-fc 융합 면역조절 단백질의 투여 및 치료 방법
US20240092921A1 (en) 2022-04-25 2024-03-21 Visterra, Inc. Antibody molecules to april and uses thereof
WO2024077018A2 (fr) 2022-10-04 2024-04-11 Alpine Immune Sciences, Inc. Procédés et utilisations d'une protéine immunomodulatrice de fusion taci-fc
WO2024092240A1 (fr) * 2022-10-28 2024-05-02 Chinook Therapeutics, Inc. Traitement de la néphropathie à iga à l'aide d'un antagoniste du récepteur de l'endothéline et d'un anticorps de liaison à april

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US778A (en) 1838-06-12 Thomas wright
US4946A (en) 1847-01-26 Improvement in carriage-wheels
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD272023A3 (de) 1985-12-04 1989-09-27 Ilmenau Tech Hochschule Vorrichtung, insbesondere zur praezisionslichtstrahlablenkung
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1988007089A1 (fr) 1987-03-18 1988-09-22 Medical Research Council Anticorps alteres
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
EP0792278B1 (fr) 1994-11-07 2007-06-13 Human Genome Sciences, Inc. Polypeptide gamma appartenant a la famille des facteurs de necrose tumorale (fnt)
US6171787B1 (en) 1997-06-26 2001-01-09 Abbott Laboratories Member of the TNF family useful for treatment and diagnosis of disease
CA2303615A1 (fr) 1997-09-12 1999-03-18 Jurg Tschopp Nouveaux ligands de la famille des tnf
WO2001060397A1 (fr) * 2000-02-16 2001-08-23 Genentech, Inc. Utilisation d'agonistes ou d'antagonistes pour moduler l'activite de molecules associees au tnf
WO2001096528A2 (fr) 2000-06-15 2001-12-20 Human Genome Sciences, Inc. Facteur de necrose tumorale humain delta et epsilon
US7189820B2 (en) 2001-05-24 2007-03-13 Human Genome Sciences, Inc. Antibodies against tumor necrosis factor delta (APRIL)
WO2003086310A2 (fr) 2002-04-12 2003-10-23 Ramot At Tel Aviv University Ltd. Prevention de l'inflammation du cerveau en tant que resultat d'une reponse auto-immune induite
US7410483B2 (en) 2003-05-23 2008-08-12 Novare Surgical Systems, Inc. Hand-actuated device for remote manipulation of a grasping tool
WO2005120571A2 (fr) 2004-06-07 2005-12-22 Ramot At Tel Aviv University Ltd. Procede d'immunisation passive contre des maladies ou des troubles caracterise(e)s par agregation amyloide a risque diminue de neuroinflammation
UY30776A1 (es) * 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
EA201170028A1 (ru) 2008-07-02 2011-12-30 Эмерджент Продакт Дивелопмент Сиэтл, Ллс СВЯЗЫВАЮЩИЕ НЕСКОЛЬКО МИШЕНЕЙ БЕЛКИ, ОБЛАДАЮЩИЕ АНТАГОНИСТИЧЕСКИМ ДЕЙСТВИЕМ TNF-α
CN102239180B (zh) * 2008-08-18 2014-12-31 辉瑞大药厂 抗ccr2抗体
MX2011002838A (es) * 2008-09-19 2011-07-29 Medimmune Llc Anticuerpos contra homologos sonic hedgehog y usos de los mismos.
EP2403528B1 (fr) 2009-03-02 2016-04-20 Aduro Biotech Holdings, Europe B.V. Anticorps contre le ligand a induisant la prolifération (april)
CN101928345B (zh) * 2010-06-21 2012-08-29 中国科学技术大学 一种人源化抗体及其人源化改造方法
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
DK3380522T3 (da) * 2015-11-25 2024-01-22 Visterra Inc Antistofmolekyler til april og anvendelser deraf

Also Published As

Publication number Publication date
US20210221900A1 (en) 2021-07-22
JP2018502918A (ja) 2018-02-01
BR112017014771A2 (pt) 2018-01-23
CA2973286A1 (fr) 2016-07-14
MX2017009052A (es) 2018-04-11
EP3242892B1 (fr) 2021-10-20
JP2021072801A (ja) 2021-05-13
KR102612373B1 (ko) 2023-12-13
EP4029879A1 (fr) 2022-07-20
US10961316B2 (en) 2021-03-30
HK1243435A1 (zh) 2018-07-13
PL3242892T3 (pl) 2022-02-21
NL2014108B1 (en) 2016-09-30
EA201791270A1 (ru) 2017-12-29
DK3242892T3 (da) 2022-01-24
EP3242892A1 (fr) 2017-11-15
WO2016110587A1 (fr) 2016-07-14
KR20170099992A (ko) 2017-09-01
CN107207602A (zh) 2017-09-26
US9969808B2 (en) 2018-05-15
JP7060728B2 (ja) 2022-04-26
KR20230170120A (ko) 2023-12-18
US10377830B2 (en) 2019-08-13
NL2014108A (en) 2016-09-23
ZA201704920B (en) 2018-11-28
CN107207602B (zh) 2021-05-25
SG11201705589UA (en) 2017-08-30
IL253306B (en) 2021-06-30
JP6824190B2 (ja) 2021-02-03
US20160264674A1 (en) 2016-09-15
AU2016205977A1 (en) 2017-08-31
ES2902901T3 (es) 2022-03-30
US20200079859A1 (en) 2020-03-12
MX2022007774A (es) 2022-08-10
IL253306A0 (en) 2017-09-28
US20180258176A1 (en) 2018-09-13
ZA201804317B (en) 2019-09-25
AU2016205977B2 (en) 2021-11-04

Similar Documents

Publication Publication Date Title
MA41313A (fr) Anticorps de liaison de la protéine april modifiés
MA47323A (fr) Protéines de liaison icos
MA47694A (fr) Anticorps anti-tigit
MA45004A (fr) Anticorps spécifiques anti-wt1-hla
MA49034A (fr) Anticorps anti-lag3
DK3292137T3 (da) Proteiner specifikke for cd137
MA44885A (fr) Protéines de liaison bispécifiques et leurs utilisations
DK3292141T3 (da) Fusionsproteiner
MA53297A (fr) Anticorps anti-icos
MA46057A (fr) Anticorps anti-ctla4
DK3344654T3 (da) Anti-lag-3-antistoffer
MA43219A (fr) Polypeptides de liaison d'antigène dirigés contre cd38
DK2970464T3 (da) Anti-lag-3-bindende proteiner
MA53616A (fr) Protéines bispécifiques modifiées
DK3350218T3 (da) Polyomavirus-neutraliserende antistoffer
DK3606961T3 (da) Garp-tgf-beta-antistoffer
MA53887A (fr) Anticorps à liaison protofibrille a-bêta améliorée
DK3325514T3 (da) Her2-bindende proteiner baseret på di-ubiquitin-muteiner
MA42843A (fr) Anticorps anti-cd115
DK3250593T3 (da) Anti-transthyretin-antistoffer
DK3253785T3 (da) Hidtil ukendte egfr-bindingsproteiner
MA50908A (fr) Formulations de protéines de fusion vegfr-fc
DK3377634T3 (da) Bakteriebaseret proteinafgivelse
MA51134A (fr) Anticorps anti-alpha-synucléine
DK3262168T3 (da) Værtscelleproteinmodifikation